{"id":534945,"date":"2021-03-22T20:20:02","date_gmt":"2021-03-22T20:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=534945"},"modified":"2021-03-22T20:20:02","modified_gmt":"2021-03-22T20:20:02","slug":"neuromyelitis-optica-spectrum-disorder-market-size-and-share-epidemiology-and-market-research-forecast-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuromyelitis-optica-spectrum-disorder-market-size-and-share-epidemiology-and-market-research-forecast-2030-by-delveinsight_534945.html","title":{"rendered":"Neuromyelitis Optica Spectrum Disorder Market Size and Share, Epidemiology and Market Research Forecast 2030 by DelveInsight"},"content":{"rendered":"
\"Neuromyelitis<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology and Market Forecast 2030<\/strong><\/a>.<\/p>\n

\"\"<\/p>\n

Neuromyelitis Optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).<\/p>\n

DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Report 2030<\/strong><\/a>“<\/span> delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period (days or weeks) but, after the initial episode, no recurrence.<\/p>\n

It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).<\/p>\n

Request for free sample pages of the report: https:\/\/www.delveinsight.com\/sample-request\/neuromyelitis-optica-spectrum-disorder-nmosd-market<\/a><\/strong><\/p>\n

NMOSD can affect children as young as 3 years and adults as old as 90 years. The onset of NMOSD varies from childhood to adulthood, and the average age of onset is about 40.<\/p>\n

NMOSD Treatment Options:<\/strong><\/p>\n

    \n
  1. Preventive <\/span>treatment <\/span>(immunosuppressive medications, mycophenolate mofetil, Azathioprine and rituximab)<\/li>\n
  2. Approved <\/span>therapy <\/span>(Soliris (eculizumab), Uplinza (inebilizumab-cdon), Enspryng (satralizumab))<\/li>\n
  3. Acute <\/span>treatment <\/span>(methylprednisolone, corticosteroids)<\/li>\n
  4. Symptomatic <\/span>treatment<\/span> (anti-epileptic medications, anti-spasmodics)<\/li>\n<\/ol>\n

    NMOSD Key pharma players involved:<\/strong><\/p>\n

      \n
    1. Bio-Thera Solutions<\/span><\/li>\n
    2. RemeGen<\/span><\/li>\n
    3. Harbour <\/span>BioMed<\/span><\/li>\n<\/ol>\n

      The NMOSD market size<\/span> shall grow during the forecast period owing to the launch of upcoming therapies and is expected to increase at a CAGR of XX during the study period.<\/p>\n

      Click here and download sample pages of the report.<\/strong><\/a><\/p>\n

      Table of contents:<\/strong><\/p>\n

      1 Key Insight
      2 Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)  market
      3 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Market Overview at a Glance
      4 Disease Background and Overview: Neuromyelitis Optica Spectrum Disorder (NMOSD)  market,
      5 Case Reports
      6 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Epidemiology and Patient Population
      7 United States Epidemiology
      8 EU5 Epidemiology
      9 Japan Epidemiology
      10 Current Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Treatment and Medical Practices
      11 Unmet needs
      12 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Marketed Drugs
      13 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Emerging Drugs
      14 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, 7MM Market Analysis
      15 United States
      16 EU-5 countries: Market Outlook
      17 Japan Market Outlook
      18 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Market Drivers
      19 Neuromyelitis Optica Spectrum Disorder (NMOSD)  market, Market Barriers
      20 SWOT Analysis
      21 Reimbursement and market access
      22 Appendix
      23 DelveInsight Capabilities
      24 Disclaimer
      25 About DelveInsight<\/p>\n

      Download report: https:\/\/www.delveinsight.com\/report-store\/neuromyelitis-optica-spectrum-disorder-nmosd-market<\/a><\/strong><\/p>\n

      About DelveInsight<\/strong>
      DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-534945","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=534945"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534945\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=534945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=534945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=534945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}